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Abstract
Background: A new generation of diagnostic tests, the interferon-γ release assays (IGRAs), have
been developed for the detection of latent tuberculosis infection (LTBI). Limited data are available
on their use in HIV-infected persons.
Methods: A cross-sectional study was carried out at 2 HIV clinics in Atlanta to assess the utility
of two IGRA tests (T-SPOT.TB [TSPOT] and QuantiFERON-TB Gold in Tube [QFT-3G])
compared to the tuberculin skin test (TST).
Results: 336 HIV-infected persons were enrolled. Median CD4 count was 335 cells/μl and median
HIV viral load was 400 copies/ml. Overall, 27 patients (8.0%) had at least 1 positive diagnostic test
for LTBI: 7 (2.1%) had a positive TST; 9 (2.7%) a positive QFT-3G; and 14 (4.2%) a positive TSPOT.
Agreement between the 3 diagnostic tests was poor: TST and TSPOT, [κ = 0.16, 95% CI (-0.06,
0.39)], TST and QFT-3G [κ = 0.23, 95% CI (-0.05, 0.51)], QFT-3G and TSPOT [κ = 0.06, 95% CI
(-0.1, 0.2)]. An indeterminate test result occurred among 6 (1.8%) of QFT-3G and 47 (14%) of
TSPOT tests. In multivariate analysis, patients with a CD4 ≤ 200 cells/μl were significantly more
likely to have an indeterminate result [OR = 3.6, 95% CI (1.9, 6.8)].
Conclusion: We found a low prevalence of LTBI and poor concordance between all 3 diagnostic
tests. Indeterminate test results were more likely at CD4 counts ≤ 200 cells/μl. Additional studies
among HIV-infected populations with a high prevalence of TB are needed to further assess the
utility of IGRAs in this patient population.
Background
The World Health Organization estimates that one third
of the world's population is infected with Mycobacterium
tuberculosis[1]. Treatment of latent tuberculosis infection
(LTBI) has been emphasized as a major strategy for TB
control and prevention particularly in the U.S. [2]. Those
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with HIV are at greatest risk of progression from infection
with M. tuberculosis to development of active disease. In
immunocompetent patients with LTBI the lifetime risk of
progression to active disease is 5–10% [3]. However
among patients with LTBI who have HIV co-infection the
annual risk of progression is 8% [4]. Given this extremely
high risk, diagnosis and treatment of LTBI among HIV-
infected individuals is strongly emphasized as an impor-
tant TB control strategy [4-6] and treatment of LTBI mark-
edly reduces the risk of progression to active disease[7].
In order to enhance TB control efforts, there is an urgent
need for new and better diagnostics. For more than a cen-
tury the only test available to identify LTBI was the tuber-
culin skin test (TST). This test has a number of limitations
including (1) reader variability; (2) false-positive test
results due to cross-reactivity with environmental non-
tuberculous mycobacteria and BCG; (3) false-negative test
results due to anergy in immunosuppressed individuals;
and (4) inconvenience to patients as they are required to
return to get the test read [2].
In recent years, a new generation of diagnostic tests for
LTBI, the T-cell based interferon-γ release assays (IGRAs),
have been developed: QuantiFERON TB Gold in Tube test
(QFT-3G) (Cellestis, Carnegie, Australia) and T-SPOT.TB
(TSPOT) (Oxford Immunotec, Abingdon, UK) [8,9].
IGRAs measure the amount of interferon-γ released from
sensitized T cells after exposure to M. tuberculosis antigens.
These include early secreted antigenic target 6 (ESAT-6)
and culture filtrate protein 10 (CFP-10), which are
encoded by genes in the region of difference 1 (RD1) seg-
ment of the M. tuberculosis genome [9]. An additional anti-
gen TB7.7 is included in QFT-3G. These antigens are more
specific than those in the purified protein derivative
(PPD) because they do not cross-react with BCG or M.
avium complex [8]. However they do cross-react with M.
kansasii, M. marinum M. szulgai and virulent strains of M.
bovis [10]. The amount of interferon-γ released is meas-
ured using either an enzyme linked immunosorbent assay
(ELISA) for QFT-3G or enzyme linked immunospot assay
(ELISPOT) for TSPOT. The advantages of IGRAs over TST
include better specificity, ability to perform serial tests
without boosting, and logistical convenience [11].
The Centers for Disease Control and Prevention (CDC)
has recommended that the currently FDA-approved
whole blood IGRA (QuantiFERON-TB Gold) can be used
as a diagnostic test for LTBI in place of the tuberculin skin
test [12]. However, there are very limited data on the use
of IGRAs among HIV-infected persons. There is only one
published study that has compared both IGRAs with TST
in HIV-infected individuals, and this study was limited by
a small sample size [13]. CDC and others have noted that
additional research is needed and recommend caution in
the use of IGRAs among HIV-infected persons [6,11].
The purpose of our study was to: 1) assess the prevalence
of LTBI among urban HIV-infected persons; 2) assess the
utility of IGRAs, specifically TSPOT and QFT-3G, among
HIV-infected persons; 3) assess the degree of concordance
among three diagnostic tests for LTBI (TST, QFT-3G, and
TSPOT); and 4) assess risk factors associated with indeter-
minate IGRA test results.
Methods
Study Design, Setting and Population
A cross-sectional study was carried out at 2 HIV clinics in
Atlanta (Grady Health System Ponce de Leon Center and
the DeKalb Board of Health) from September 2005 – July
2006. The study was approved by the Emory University
Institutional Review Board (IRB) as well as IRBs at CDC
and the Georgia Department of Human Resources.
Patients who had positive serologic tests for HIV and were
≥ 18 years of age were eligible for enrollment into the
study. All enrolled persons provided written informed
consent. Demographic data, medical history, and history
of BCG vaccination were obtained from medical records
and patient interviews and entered on a data abstraction
form. CD4 counts and HIV viral load levels were obtained
from medical records and were performed within a 3-
month period from the time of enrollment in the study.
Interferon-γ Release Assays and Tuberculin Skin Testing
A trained technician who was blinded to the patients'
medical history and TST results performed both IGRAs.
The TSPOT test was performed as previously described
and according to manufacturer's instructions [14]. Briefly,
peripheral blood mononuclear cells (PBMCs) were
obtained and counted to ensure that each well was plated
with a minimum of 2.5 × 105 cells. Plates were incubated
overnight to allow for antigen stimulation and release of
interferon-γ. After incubation the wells were developed
using an enzyme-conjugated secondary antibody to the
interferon-γ. Colored spots were generated by the conju-
gated enzyme upon application of a colorimetric sub-
strate. Spot-forming units were counted by a trained
technician using a standardized magnifying lens. Spots
were also counted using an AID ELISPOT Reader (ER).
The technician doing the visual counting and those deter-
mining the number of spot-forming cells by ER were
blinded to each other's results. The TSPOT was considered
reactive if the response to either the ESAT 6 or CFP10
minus the negative control was ≥ 6 spot forming cells, or
> 2 × the negative control. The result was considered inde-
terminate if the reading in the negative control was > 20
spot forming cells or if the reading in the positive control
was < 20 spot forming cells.BMC Infectious Diseases 2009, 9:15 http://www.biomedcentral.com/1471-2334/9/15
Page 3 of 9
(page number not for citation purposes)
For QFT-3G, 1-ml aliquots of blood were collected in
three tubes, one with the negative control, one with the
positive control and one with TB specific antigens. The test
was performed as previously described and per the manu-
facturer's instructions [15]. Blood samples were centri-
fuged and incubated overnight. After incubation, plasma
was harvested and concentrations of interferon-γ were
measured by ELISA. The QFT-3G was considered positive
if the interferon-γ response to TB antigens minus the neg-
ative control was ≥ 0.35 IU/ml and > 25% of the negative
control; negative if these criteria were not met; and inde-
terminate if either the negative control had a result of > 8
IU/ml or the positive control had a result of < 0.5 IU/ml.
After blood was drawn for the IGRAs, a TST was placed
using the Mantoux method [16]; 0.1 ml (5 TU) of PPD
(Tubersol; Sanofi Pasteur Inc., Swiftwater, PA) was placed
intradermally. The TST was measured by a trained reader
between 48 and 72 hours. Induration of ≥ 5 mm was con-
sidered positive [16].
Statistical analyses
Data were entered into an Access database (Microsoft,
Redmond, WA) and analyzed using SAS (SAS Institute Inc.
version 9.1, Cary, NC). Outcomes included prevalence of
LTBI, concordance between tests, factors associated with a
positive and indeterminate test result. Both concordance
between the diagnostic tests for LTBI (IGRAs and TST) and
concordance between TSPOT results by visual inspection
versus an ELISPOT reader were measured. All reported
TSPOT results are based on results from the ELISPOT
reader. Concordance was assessed using κ, where κ >0.75
represents excellent agreement, κ values from 0.4–0.75
represent fair to good agreement and κ < 0.4 represents
poor agreement, beyond chance [17]. Risk factors for test
positivity were evaluated using prevalence odds ratios
(OR). Due to the small number of positive test results (as
a result of the low prevalence of LTBI), in most instances
only univariate analysis was performed. Variables that
were looked at included age, sex, race, CD4 count, HIV
viral load, and selected elements of initial medical history
such as history of BCG vaccination, prior history of LTBI
or AIDS-defining malignancy. Prior history of LTBI was
defined as a positive TST in the past. Multivariate logistic
regression model was used to assess factors associated
with a positive TSPOT result. The multivariate model
included age, race, CD4 count and HIV viral load. A mul-
tivariate logistic regression was also used to assess factors
associated with indeterminate IGRA test results. Predictors
in the final model were age, sex, race and CD4 count. Cor-
relation was also assessed between CD4 counts and inter-
feron-γ values for QFT-3G, and CD4 counts and spot




A total of 336 HIV-infected persons were enrolled. The
baseline characteristics of the patient population are
shown in Table 1. The median CD4 count was 335 cells/
μl (range 0–1380 cells/μl) and 101 (30.1%) patients had
a CD4 count ≤ 200 cells/μl. Median viral load was 400
copies/ml (< 50 to > 750,000 copies/ml), and median
duration of HIV diagnosis was 8 years. Two hundred
thirty-one patients (69%) were on antiretroviral therapy
at the time of enrollment in the study.
Diagnostic Tests for Latent Tuberculosis Infection (LTBI)
Overall, 27 (8.0%) of 336 patients had at least one posi-
tive diagnostic test for LTBI. Among the 278 patients who
had their TST read, seven (2.5%) were positive; 9 of the
336 patients (2.7%) had a positive QFT-3G; and 14 of the
336 patients (4.2%) had a positive TSPOT using an ELIS-
POT reader (ER) (Table 2). Only 3 patients had a positive
result for more than 1 diagnostic test, and only 1 patient
had positive test results for all 3 diagnostic tests (TST,
QFT-3G, and TSPOT).
Tuberculin Skin Test (TST)
TST results were available for 278 (82.7%) persons. Seven
patients (2.5%) had a positive TST with a mean indura-
tion of 16 mm (range 11–25 mm). All patients with a pos-
itive TST had a CD4 count ≥ 200 cells/μl. There was no
difference in the mean CD4 count of patients with a pos-
itive skin test as compared to a negative skin test (448
cells/μl versus 369 cells/μl, p = 0.5).
Interferon-γ Release Assays (IGRAs): QuantiFERON-TB 
Gold In Tube (QFT-3G) and T-SPOT.TB (TSPOT)
QFT-3G
Nine patients (2.7%) had a positive QFT-3G, 321 patients
(95.5%) had a negative result, and 6 patients (1.8%) had
an indeterminate test result. The median amount of inter-
feron-γ produced in response to the mitogen was > 10 IU/
ml (range 0.2–> 10 IU/ml). The median amount of inter-
feron-γ produced in response to TB specific antigens was
0.03 IU/ml (range 0–> 10 IU/ml). Among patients with a
positive QFT-3G test result; the median interferon-γ
response to TB specific antigens was 0.7 IU/ml (range 0.4–
3.5 IU/ml).
There was no difference between the mean CD4 counts of
patients with a positive versus a negative QFT-3G (441
cells/μl and 367 cells/μl, p = 0.3). There was a significant
correlation between the CD4 count and interferon-γ
response to mitogen. (ρ = 0.44, p < 0.001). There was no
significant correlation between CD4 count and inter-
feron-γ response to TB specific antigens (ρ = 0.1, p = 0.08).
There was no association between the degree of indura-
tion with TST and the interferon-γ response to TB specificBMC Infectious Diseases 2009, 9:15 http://www.biomedcentral.com/1471-2334/9/15
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Table 1: Baseline characteristics of population, enrolled at two urban HIV clinics (n = 336).
Patient Characteristics Numbers and Percentages
Age










Born outside the United States 29 (8.6%)
HIV History
CD4 count, median and range 334 (0–1380 cells/μl)
Viral load, median and range 400 (< 50–> 750,000 copies/ml)
Duration of HIV diagnosis, median and range 8 (0–26 years)
Patients on HAART 231 (68.8%)
History of opportunistic infection 202 (60%)
Past Medical History
Prior history of latent tuberculosis infection 7 (2.1%)
History of BCG vaccination 25 (7.4%)
Diabetes mellitus 23 (6.9%)
Chronic renal insufficiency 12 (3.6%)
History of malignancy 14 (4.2%)
Anytime smoker 186 (55.4%)
Intravenous drug use 64 (19%)
HIV = Human Immunodeficiency Virus
HAART = Highly Active Antiretroviral Therapy
BCG = Bacille Calmette-Guérin
Table 2: Prevalence of a Positive Diagnostic Test for Latent Tuberculosis Infection




At least 1 positive test 27 (8.0%)
All 3 tests positive 1 (0.3%)
TST = Tuberculin Skin Test
QFT-3G = QuantiFERON-TB Gold in Tube
TSPOT = T-SPOT. TBBMC Infectious Diseases 2009, 9:15 http://www.biomedcentral.com/1471-2334/9/15
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antigens (ρ = 0.08, p = 0.2). In univariate analysis the only
factor associated with a positive QFT-3G was a past history
of malignancy (OR = 6.8, 95% CI 1.3, 36.4).
TSPOT
Fourteen persons (4.2%) had a positive TSPOT using an
ELISPOT reader (ER), 275 patients (81.8%) had a negative
test, and 47 patients (14.0%) had an indeterminate test
result. There was no difference in CD4 counts among
patients with a positive compared to those with a negative
TSPOT test (303/μl versus 372/μl, p = 0.3). The mean
number of spots for panel A (ESAT-6) was 3 spot forming
cells, (range 0–167) and for panel B (CFP 10) was 2.1 spot
forming cells (range 0–660).
There was no correlation between the CD4 count and
interferon-γ response to mitogen (ρ = 0.01, p = 0.8) or
interferon-γ response to ESAT-6 or CFP 10 (ρ = 0.02, p =
0.8 and ρ = 0.1, p = 0.07 respectively). However, there was
a significant association between the degree of induration
with TST and the interferon-γ response to ESAT-6 and
CFP-10 (ρ = 0.16, p = 0.007). In univariate analysis and
multivariate analysis, a positive TSPOT was associated
with a prior history of LTBI (univariate OR = 10.5, 95% CI
1.9, 59.9, multivariate OR = 10, 95% CI 1.7, 59.7).
The number of persons with a positive TSPOT and an
indeterminate test differed when using the ELISPOT
Reader compared to visual readings with a magnifying
glass. There was moderate concordance between ER and
visual inspection [κ = 0.58 (95% CI 0.47, 0.68)] (Table 3).
Results from the ER were used in assessing prevalence and
risk factors for a positive test and concordance with the
other diagnostic tests.
Concordance between Diagnostic Tests
A total of 3 patients had a positive result for more than 1
diagnostic test and 1 patient tested positive for TST, QFT-
3G, and TSPOT. There was poor concordance between TST
and QFT-3G [κ = 0.23, (95% CI -0.05, 0.51)] (Table 4),
between TSPOT and TST [κ = 0.16, (95% CI -0.06, 0.39)]
(Table 5), and between the two IGRAs, QFT-3G vs TSPOT
[κ = 0.06, 95% CI (-0.1, 0.2)] (Table 6). In univariate anal-
ysis, TST-positive/QFT-3G-negative discordance was asso-
ciated with a history of BCG vaccination (OR = 8.0, 95%
CI 1.3, 50.7) and a prior history of LTBI (OR = 16.0, 95%
CI 1.4, 177). TST-positive/TSPOT-negative discordance
was associated with BCG vaccination (OR 17.7, 95% CI
1.9, 167). TSPOT-positive/QFT-3G-negative discordance
was associated with a prior history of LTBI (OR = 13.7,
95% CI 2.0, 93.6). No risk factors were found to be asso-
ciated with QFT-3G-positive/TST-negative, QFT-3G-posi-
tive/TSPOT-negative, or TSPOT-positive/TST-negative
discordance.
Impact of Varying Cutoff Values on Concordance
A QFT-3G test is considered positive if the interferon-γ is
≥ 0.35 IU/ml based on previously published data and the
manufacturer's recommendations [9]. Lowering the cutoff
value for a positive QFT-3G to ≥ 0.05, ≥ 0.15 and ≥ 0.25
IU/ml did not impact concordance between tests. The cut-
off for a positive TSPOT test is ≥ 6 spot forming cells,
decreasing the cutoff value of a positive TSPOT to ≥ 5
spots, ≥ 4 spots, ≥ 3 spots did not improve concordance
between tests. We evaluated the impact of CD4 counts on
concordance by measuring κ in patients with CD4 counts
≥ 200/μl,  ≥ 300/μl, and ≥ 400/μl. There was a slight
increase in κ values at higher CD4 counts, but concord-
ance remained poor.
Risk Factors for an Indeterminate TSPOT or QFT-3G Test 
Result
An indeterminate test result occurred in 6 patients (1.8%)
with QFT-3G. Five occurred due to an inadequate mitogen
response and one occurred due to high background levels
of interferon-γ in the negative control. In univariate anal-
ysis, there was no significant association between an inde-
terminate QFT-3G and a CD4 count ≤ 200/μl (OR = 4.8,
95% CI 0.9, 26.8).
An indeterminate TSPOT result occurred in 47 patients
(14%). Twenty-eight patients had an inadequate inter-
feron-γ response to the mitogen, 14 had insufficient cells,
and 5 patients had high background levels of interferon-γ
in the negative control. In multivariate analysis, for
TSPOT, a CD4 count ≤ 200/μl was associated with an
Table 3: Comparison of TSPOT results by ELISPOT reader (ER) vs Visual Exam (VE).




Negative by VE 02 4 4 1 6
Invalid by VE 11 4 3 0
κ = 0.58, 95% CI (0.47, 0.68)BMC Infectious Diseases 2009, 9:15 http://www.biomedcentral.com/1471-2334/9/15
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increased risk of an indeterminate test result (OR = 3.4,
95% CI 1.8, 6.5). We then pooled data for the indetermi-
nate QFT-3G and indeterminate TSPOT and found that a
CD4 count ≤ 200/μl was associated with an indeterminate
IGRA test (OR = 3.6, 95% 1.9, 6.8) (Table 7).
Discussion
To our knowledge this is the largest study to date to look
at TST, TSPOT and QFT-3G in HIV seropositive persons.
The most striking finding in our study was the poor con-
cordance found between the three different tests with κ
values ranging from 0.06–0.23. The overall prevalence of
a positive test with TST was 2.5%, by QFT-3G was 2.7%
and TSPOT was 4.2%. However only three people tested
positive with more than one test and only one person
tested positive for all three tests. Other studies from coun-
tries with a low prevalence of TB have also found poor
concordance between TST and QFT-3G [15,18,19]. How-
ever no other study has looked at concordance between
TST and TSPOT in low prevalence countries. In studies
from Africa concordance between TST and IGRAs has
been fair [13,20].
We evaluated whether lowering the interferon-γ cutoff
would improve concordance between tests since the cur-
rent cutoff values are based on receiver operator character-
istics in immunocompetent individuals and it is known
that HIV-infected patients have impaired interferon
responses [21]. Lowering the interferon cutoff did not
improve concordance. Studies have shown that TST is
more reliable at CD4 counts ≥ 100/μl [22]. We wanted to
define a similar CD4 cutoff for IGRAs. However, limiting
analysis to patients with higher CD4 counts did not
improve concordance in our study population.
Another finding from our study was that TSPOT test gave
the largest number of positive results which has also been
confirmed in other studies [20]. On univariate analysis we
found a prior history of LTBI was associated with a posi-
tive TSPOT and with TSPOT positive/QFT-3G negative
discordance suggesting that perhaps TSPOT is a more sen-
sitive test. However these results need to be confirmed
with multivariate analysis in a larger study. A meta-analy-
sis showed that TSPOT was more sensitive than QFT-3G at
diagnosing active TB [11]. Contact investigation studies in
both immunocompetent and immunocompromised
hosts have shown that TSPOT is more likely to be positive
than TST [23-25] and QFT-3G [26].
Our study is the first to compare the results from TSPOT
read with a magnifying lens and those with an ELISPOT
reader and found moderate agreement between the tests.
However if we had relied on only the magnifying lens we
would have had 31 tests positive as opposed to 14. We feel
results are likely to be more accurate when interpreted
using an ELISPOT reader. If these tests do become availa-
ble in developing countries the cost of the ELISPOT
Reader will need to be considered when deciding what test
to use.
Table 4: Degree of Concordance among Three Diagnostic Tests for Latent Tuberculosis Infection Concordance between TST and 
QFT-3G
QFT-3G




Positive TST (n = 7)
(> 5 mm induration)
25 0
Negative TST 72 5 9 5
TST not read 05 8 0
κ = 0.23, 95% CI (-0.05, 0.51).
Table 5: Concordance between TST and TSPOT




Negative TST 10 219 42
TST not read 25 2 4
κ = 0.16, 95% CI (-0.06, 0.39).BMC Infectious Diseases 2009, 9:15 http://www.biomedcentral.com/1471-2334/9/15
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Another issue that arises in using IGRAs in immunocom-
promised persons is the rate of indeterminate test results.
In our study an indeterminate test result occurred in 14%
of patients with TSPOT and 1.8% of patients with QFT-
3G. The high rate of indeterminate TSPOT tests likely
occurred due to inadequate CD4 cells. Other studies in
HIV seropositive individuals have also found that around
10% of patients have an indeterminate result [20]. In our
study an indeterminate result was associated with a CD4
count of < 200 cells/μl. Patients with indeterminate
results will require retesting, testing with a larger volume
of blood (in order to obtain more PBMCs for TSPOT), or
use of a different diagnostic test. It is unclear therefore
how useful these tests will be in severely immunocompro-
mised patients.
Our study is subject to several limitations. The low preva-
lence of positive test results limited our ability to evaluate
risk factors associated with positive test results and factors
associated with discordance. Studies in countries with a
higher prevalence of LTBI may help overcome this prob-
lem. In addition, the lack of a gold standard makes it dif-
ficult to determine which diagnostic test is more sensitive
or specific for LTBI.
Given the results of our study and the limited data cur-
rently available in the literature, it is unclear if IGRAs can
be used alone for diagnosis of LTBI in HIV-infected indi-
viduals. Some authors have suggested a combined
approach of TST and IGRA [15]. We feel this would lead
to confusion for physicians when there are discordant
results. Questions that remain are whether in high-inci-
dence countries there is better concordance between
IGRAs and TST; can we define a lower interferon-γ cutoff
value for patients who are immunocompromised or have
HIV; is there a CD4 cutoff value below which these tests
are no longer useful; and is IGRA positivity an accurate
predictor of progression to active TB.
Conclusion
In conclusion, we report the largest study to date to assess
the use of IGRAs in HIV-infected persons. Our findings
indicate a low prevalence of LTBI, poor concordance
between the TST and IGRAs and high rates of indetermi-
nate test results in patients with CD4 counts ≤ 200 cells/
μl. Additional studies, preferably with a longitudinal
design in HIV-infected individuals and other immuno-
compromised patients in various clinical settings, are
needed to determine the true role IGRAs will play in the
diagnosis of LTBI in such patients.
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